Skip to navigation menu Skip to content
Informational Alert

Learn about progress on health equity and anti-racism efforts in Seattle Children’s fourth quarterly report.


Blood Cancers

Our team has been developing a new CD200R-based IFP to improve in vivo anti-tumoral T-cell function against acute myeloid leukemia (AML).

Solid Tumors

In mouse models of ovarian and pancreatic cancers, mice with our IFP-enhanced cell therapy were able to destroy repeated additions of tumor cells, whereas control T cells became dysfunctional and ineffective.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies